Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Castle Securities: Retail Investor Sentiment Dims, Historical Patterns Suggest Short-Term US Stock Market Rebound Possible

Castle Securities: Retail Investor Sentiment Dims, Historical Patterns Suggest Short-Term US Stock Market Rebound Possible

CointimeCointime2026/04/07 17:27

On April 8, Castle Securities strategists indicated that the dimming sentiment among retail investors may signal a potential short-term rebound in the US stock market. Scott Rubner, head of equity and equity derivatives strategy at Castle Securities, stated that according to the company's platform data, individual traders turned into net sellers of US stocks and options last week. Traditionally, retail investors have been one of the most bullish groups in the stock market. This situation has only occurred 18 times since January 2020. In the previous weeks, the war in Iran and soaring oil prices triggered significant volatility in the stock market. In a report to clients on Tuesday, Rubner wrote, 'We are now seeing initial signs of capitulation among retail investors in both the spot and options markets, and retail participation is no longer a one-sided source of demand.' This bearish shift is a clear deviation from the behavior pattern of retail investors who have consistently bought on dips in recent years. However, data from Castle Securities shows that historically, periods of retail investor fatigue often coincide with stronger short-term returns in the US stock market: after similar signals, there is about an 82% probability that the S&P 500 will rise over the next two months, with an average increase of 4.1%.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12